

Corporate Presentation References

Armand, P., et al., *Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation*. Blood, 2014. **123**(23): p. 3664-71. ([PDF](#))

Assessment report Zalmoxis June 2016 ([PDF](#))

Bentley, T.S., *T αβ/CD19 depletion in haploidentical transplantation prevents GVHD and allows a prompt and effective immune reconstitution in adult patients with acute leukemia*. Milliman Research Report 2014. ([PDF](#))

Besse, K.L., et al., *Estimating demand and unmet need for allogeneic hematopoietic cell transplantation in the United States using geographic information systems*. J Oncol Pract, 2015. **11**(2): p. e120-30 ([PDF](#))

CIBMTR 2016 Summary Slides ([website](#))

Ciurea, S.O., et al., *Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation*. Biol.Blood Marrow Transplant., 2012. **18**(12): p. 1835-1844 ([PDF](#))

Ciurea, S.O., et al., *Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia*. Blood, 2015. **126**(8): p. 1033-1040 ([PDF](#))

Deol, A. and L.G. Lum, *Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited*. Cancer Treat Rev, 2010. **36**(7): p. 528-38 ([PDF](#))

Devillier, R., et al., *T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes*. Bone Marrow Transplant, 2016. **51**(2): p. 194-8 ([PDF](#))


Di Stasi, A., et al., *Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors*. Biol.Blood Marrow Transplant, 2014. **20**(12): p. 1975-1981 ([PDF](#))

Fuchs, E.J., *Related haploidentical donors are a better choice than matched unrelated donors: Point*. Blood Advances, 2017. **1**(6): p. 397-400 ([PDF](#))

Gragert, L., et al., *HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry*. N Engl J Med, 2014. **371**(4): p. 339-48 ([PDF](#))

Jones, C., et al., *Estimating the Burden of Cost in Chronic Graft-versus-Host Disease: A Human Capital Approach*. Journal of Health Economics and Outcomes Research, 2016. **4**(2): p. 6 ([PDF](#))

Lang, P., et al., *Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients*. Bone Marrow Transplant, 2015. **50** Suppl 2: p. S6-10 ([PDF](#))



Corporate Presentation References

Locatelli, F., et al., *Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion*. *Blood*, 2017 ([Journal](#))

Lucia, P., et al., *T $\alpha\beta$ /CD19 depletion in haploidentical transplantation prevents GVHD and allows a prompt and effective immune reconstitution in adult patients with acute leukemia*. Poster EBMT 2017 ([EBMT Website](#))

Majhail, N.S., et al., *Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database*. *Bone Marrow Transplant*, 2013. **48**(2): p. 294-300 ([PDF](#))

McCurdy, S.R., et al., *Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide*. *Haematologica*, 2017. **102**(2): p. 391-400 ([PDF](#))

Merli, P., et al., *Impact of Post-Transplant Infusion of Donor T-Cells Genetically Modified with Inducible Caspase 9 Suicide Gene (BPX-501 Cells) on Children with Leukemia Given $\alpha\beta$ T-Cell and B-Cell Depleted Haplo-HSCT*. ([Bellicum Presentation](#))

Passweg, J.R., et al., *Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually*. *Bone Marrow Transplant*, 2016 ([PDF](#))

Passweg, J.R., et al., *Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report*. *Bone Marrow Transplant*, 2017. **52**(6): p. 811-817 ([PDF](#))


Piemontese, S., et al., *A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia*. *J Hematol Oncol*, 2017. **10**(1): p. 24 ([PDF](#))

Solh, M., et al., *Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center*. *Biol Blood Marrow Transplant*, 2016. **22**(8): p. 1403-9 ([Abstract](#))

Solomon, S.R., et al., *Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial*. *Biol.Blood Marrow Transplant.*, 2012. **18**(12): p. 1859-1866 ([PDF](#))

Sugita, J., et al., *HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning*. *Biol.Blood Marrow Transplant*, 2015. **21**(9): p. 1646-1652 ([PDF](#))

Walker, I., et al., *Canadian multicenter pilot trial of haploidentical donor transplantation*. *Blood Cells Mol.Dis.*, 2004. **33**(3): p. 222-226 ([Abstract](#))



Corporate Presentation References

Zhou, X., et al., *Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene*. *Blood.*, 2014. **123**(25): p. 3895-3905 ([PDF](#))

[1]

1. Majhail, N.S., et al., *Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database*. *Bone Marrow Transplant*, 2013. **48**(2): p. 294-300.